President Donald Trump signed an executive order on April 2, 2026, imposing tariffs of up to 100% on imported patented pharmaceutical products and active ingredients. Invoking Section 232 of the Trade Expansion Act of 1962, Trump framed the measure as a national security action to address the fact that 53% of patented drugs distributed in the U.S. are made abroad. The order establishes a tiered system, offering a 20% rate for companies that onshore manufacturing and a 0% rate for those that also sign "Most-Favored-Nation" pricing deals. Industry groups like PhRMA and BIO warned the tariffs will raise healthcare costs and jeopardize domestic investments.
Pharmaceutical tariff structure
- ▪The pharmaceutical tariffs signed on April 2, 2026, will take effect after a 120-day phase-in period for large companies and a 180-day period for smaller drugmakers.
- ▪The pharmaceutical tariffs signed by President Donald Trump on April 2, 2026, exclude generic pharmaceuticals, biosimilars, and their associated ingredients.
- ▪President Donald Trump signed an executive order on April 2, 2026, imposing tariffs of up to 100% on imported patented pharmaceutical products and active pharmaceutical ingredients.
Domestic manufacturing incentives
- ▪Under the April 2, 2026 executive order, companies that commit to onshoring their manufacturing to the United States will face a reduced tariff rate of 20%.
- ▪The 20% tariff rate for drug companies with approved onshoring plans is scheduled to rise to 100% in the year 2030.
Most favored nation pricing
- ▪The 16 large drugmakers that have entered into Most Favored Nation pricing agreements with the Trump administration will receive a tariff exemption until January 20, 2029.
- ▪Drug companies can avert the new tariffs entirely if they enter into a most-favored-nation pricing agreement and are actively building a manufacturing plant in the United States.
- ▪The Trump administration has reached 17 pricing deals with major drugmakers, 13 of which have been signed, according to a senior administration official on April 2, 2026.
National security justification
- ▪A Department of Commerce Section 232 investigation concluded that imported pharmaceuticals and ingredients enter the United States in quantities that threaten to impair national security.
- ▪President Donald Trump invoked Section 232 of the Trade Expansion Act of 1962 to justify the pharmaceutical tariffs on national security grounds.
Trade agreement exemptions
- ▪Under the April 2, 2026 executive order, patented pharmaceutical imports from the United Kingdom will face a 10% tariff, which can reduce to zero under future agreements.
- ▪The April 2, 2026 executive order excludes patented drugs imported from Switzerland, Japan, South Korea, and the European Union, which will instead face a 15% tariff.
Foreign drug production dependency
- ▪According to the presidential proclamation, approximately 53% of patented pharmaceutical products distributed in the United States are produced abroad.
- ▪According to the presidential proclamation, only 15% of patented active pharmaceutical ingredients by volume are manufactured domestically in the United States.
Debatable claims
- ▪Trump's pharmaceutical tariffs will increase prescription drug costs for US patients
- ▪Trump's pharmaceutical tariffs unfairly disadvantage smaller biotech companies
- ▪US reliance on imported patented pharmaceuticals threatens national security
- ▪Trump's pharmaceutical tariffs will harm American biotech innovation
Story comments
Loading comments…